aEarly Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France bCancer Surveillance Branch, International Agency for Research on Cancer ...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hernexeos (zongertinib), which is a kinase inhibitor, for the treatment of adults with unresectable or metastatic ...

Cutaneous squamous-cell carcinoma (SCC) is primarily caused by oncogenesis mediated by ultraviolet radiation, and β-human papillomavirus (β-HPV) is believed to be a mere facilitator that is ...

MSK radiation oncologist Dr. Nancy Lee helped design the clinical trial showing that immunotherapy given around surgery could reduce recurrence of some head and neck cancers. A phase 3 clinical trial ...

Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or non­melanoma skin cancer, which is also known as keratinocyte ...

The findings are notable in part because therapies have already been approved to target C5aR1 in other diseases. cSCC is the most common type of metastatic skin cancer, and its incidence is increasing ...

*Note: One patient in each cohort finished treatment without at least one post-baseline tumor assessment. Among the patients with PD-L1 TPS<1%, IBI363 demonstrated outstanding efficacy signals: in the ...

Traws Pharma published promising data on rigosertib for treating RDEB-associated SCC, showing an 80% response rate in clinical trials. The company is actively seeking development and commercialization ...

Patients who have cutaneous squamous-cell carcinoma with high-risk features are at risk for recurrence after definitive local therapy. The benefit of systemic adjuvant therapy options has not been ...

A prospective, single-arm, phase II study of adebrelimab plus carboplatin and albumin-bound taxanol as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell ...